1. Home
  2. |Insights
  3. |We've Come to the End of the Road: FY 2018 Report to Congress Says DCAA Backlog is No More

We've Come to the End of the Road: FY 2018 Report to Congress Says DCAA Backlog is No More

Client Alert | less than 1 min read | 07.11.19

The Defense Contract Audit Agency (DCAA) recently made public its Fiscal Year (FY) 2018 Report to Congress (“Report”), which, among other things, reports that DCAA has eliminated its incurred cost audit backlog.

The Report also describes its industry outreach activities and DCAA’s plans to focus more attention on other audits, such as business systems, Truth in Negotiations Act, Cost Accounting standards, pre-award surveys, claims, and terminations. Those plans are discussed more fully in our blog post.  

Contacts

Insights

Client Alert | 7 min read | 09.14.26

AI in Life Sciences: Ten Legal Considerations and Risks of AI Use in Drug Discovery and Development

Over the past several years, the biopharmaceutical industry has embraced artificial intelligence and machine learning (AI/ML) in near lockstep with the pace of AI/ML innovations. Today, industry leaders are using AI/ML to, among other things: discover and assess biological pathways, target chemical structures and sequences; design proteins; model pre-clinical and clinical trials; recruit and screen potential patient populations; evaluate clinical trial results and biomarker data; prepare regulatory filings; and manage supply chains. Deployment of new AI/ML models promises extraordinary advances in pharmaceutical development. However, as with any technological and scientific advances, the use of AI/ML also poses substantial legal risks that life sciences companies need to consider and proactively manage. ...

View All Insights